God is our Guide  Number 1 site for help


CIDP info
Anti-inflammatory Diet
Burning  Feet Home
Services Page
Chronic Fatigue
Autoimmune diseases
Bible healing
Celiac disease
Natural Makeup
Cancer & Lipstick
Magic cleaner
Mercury in makeup
Toxic Lipstick
Hair chemicals
Toxic Baby products
Toxic calcium
Chemicals in soap
Kitchen toxins
Home Hazard
Organic or nonorganic
 Bras cause breast cancer
Poison at home
 Phylates in makeup
 Plastic Bags

Vitamin C benefits

blood injection therapy


Avicenna & Laws of Medicine


Daily vinegar for health

Statin Induced Dementia

 Green tea & cancer risk





 Biophosphates & Pain

   alternatives treatment of autoimmune disease read our e-book 

Special GoogleHealth Search

Bisphosphonate Therapy Linked to Risk for Severe Musculoskeletal Pain

Yael Waknine

Temporary or permanent discontinuation of bisphosphonate therapy should be considered in patients who present with severe musculoskeletal pain, the US Food and Drug Administration (FDA) warned healthcare professionals yesterday. Overlooking bisphosphonate therapy as a causal factor may delay diagnosis, thereby prolonging pain and/or impairment and the use of analgesics. In contrast with the acute-phase response that sometimes accompanies initial exposure to bisphosphonate therapy, some patients experience severe and sometimes incapacitating bone, joint, and/or muscle pain that begins months or years later.

The incidence rate and risk factors for this reaction remain unknown, according to an alert sent from MedWatch, the FDA's safety information and adverse event reporting program. Moreover, discontinuation of therapy may not lead to complete relief some patients have reported slow or incomplete resolution of symptoms.

Over the next 6 months, the FDA will be evaluating reports of severe musculoskeletal pain associated with bisphosphonate use. In the interim, patients reporting these symptoms should be monitored, and alternative causes for pain should be considered for those who do not experience a lessening or resolution of symptoms after bisphosphonate withdrawal.

Bisphosphonates are indicated for the prevention and treatment of osteoporosis and for treating hypercalcemia of malignancy and Paget's disease. They also are beneficial in patients with multiple myeloma and bone metastases from solid tumors.

Currently marketed oral bisphosphonates include risedronate sodium tablets (Actonel and Actonel + Ca, Proctor & Gamble Pharmaceuticals, Inc), alendronate sodium tablets (Fosamax and Fosamax + D, Merck & Company, Inc), ibandronate sodium tablets (Boniva, Roche), etidronate disodium tablets (Didronel, Proctor & Gamble), and tiludronate disodium tablets (Skelid, sanofi-aventis US, LLC).

Injectable bisphosphonates include pamidronate disodium injection (Aredia, Novartis Pharmaceuticals Corp) and zoledronic acid injection (Reclast and Zometa, Novartis).

Adverse events related to bisphosphonate use should be reported to the FDA's MedWatch reporting program by telephone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, online at , or by mail to 5600 Fishers Lane, Rockville, MD 20852-9787